Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy.

Mauro Marzorati, Simone Porcelli, Giuseppe Bellistri, Lucia Morandi, Bruno Grassi

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage disease type II. Previous studies have demonstrated clinical efficacy of enzyme replacement therapy, however, data on physiological variables related to exercise tolerance are scarce. Four glycogen storage disease type II late-onset patients (45 ± 6 years) performed an incremental exercise on a cycle ergometer, up to voluntary exhaustion, before (BEFORE) and after 12 months of ERT (AFTER). Peak workload, oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak workload and oxygen uptake values significantly increased during ERT (54 ± 30 vs. 63 ± 31 watt, and 17.2 ± 4.4 vs. 19.7 ± 3.5 ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, for both peak cardiac output (12.3 ± 5.3 vs. 14.8 ± 4.5 L/min) and the NIRS-determined peak skeletal muscle fractional O2 extraction, expressed as a percentage of the maximal values during a transient limb ischemia (30 ± 39% vs. 38 ± 28%), the observed increases were not statistically significant. Our findings suggest that in glycogen storage disease type II patients enzyme replacement therapy is associated with a mild improvement of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group of patients.
Original languageEnglish
Pages (from-to)230-234
Number of pages5
JournalNeuromuscular Disorders
Volume22
DOIs
Publication statusPublished - 2012
Externally publishedYes

Keywords

  • Pompe disease
  • malattia di Pompe
  • metabolismo ossidativo
  • oxidative metabolism

Fingerprint

Dive into the research topics of 'Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy.'. Together they form a unique fingerprint.

Cite this